drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR-T)
drug_description
Autologous T lymphocytes genetically modified to express dual chimeric antigen receptors targeting CD19 and CD22; antigen engagement triggers CAR signaling with costimulation, leading to T-cell expansion, cytokine release, and cytotoxic killing of malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors recognizing CD19 and CD22 on B cells. Antigen binding triggers CAR signaling (CD3ΞΆ with costimulatory domains such as CD28/4-1BB), driving T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant B cells, with on-target B-cell aplasia and reduced antigen-loss escape.
drug_name
CD19/CD22 dual-target CAR-T cells
nct_id_drug_ref
NCT07093086